Abstract
Abstract
Objectives To determine the associations between the presence of various-sized hypertransmission defects (hyperTDs) and progression to incomplete retinal pigment epithelial (RPE) and outer retinal atrophy (iRORA) and complete RORA (cRORA) in eyes with intermediate age-related macular degeneration (iAMD).Methods Optical coherence tomography (OCT) data from consecutive iAMD patients, were retrospectively reviewed. All of iAMD eyes with or without iRORA (but not cRORA) at baseline were included. Graders evaluated the presence of hyperTDs at baseline (small: 63–124 µm; medium: 125–249 µm; large: ≥ 250 µm in diameter on choroidal en face OCT) and the progression two years later.Results Of the 145 eyes that not developed neovascular AMD at two years, the eyes that progressed to or developed iRORA or cRORA included 13 eyes (10.7%), 5 eyes (83.3%), 9 eyes (81.8%), and 6 eyes (85.7%) in the groups with no, small, medium, and large hyperTDs at baseline, respectively (P-value < 0.001). The odds ratios (95% CI) for progression were 41.6 (4.5–383.6), 37.4 (7.3–192.0), and 49.9 (5.6–447.1) in the small, medium, and large hyperTDs groups, compared to no hyperTDs (P-value ≤ 0.001). Eyes with ≥ 2 hyperTDs also showed more frequent progression than eyes with one or no hyperTDs (100% vs. 16.4%; P-value < 0.001).Conclusions While most iAMD eyes with no hyperTDs remained stable on OCT over two years, eyes with hyperTDs of any size appeared to be at a higher risk for progression. HyperTDs may provide an important OCT biomarker for identifying high-risk iAMD patients.
Publisher
Research Square Platform LLC
Reference34 articles.
1. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to vision 2020: the right to sight: an analysis for the global burden of disease study;GBD 2019 Blindness and Vision Impairment Collaborators, on belhalf of Vision Loss Expert Group of the Global Burden of Disease Study;Lancet Glob Health,2021
2. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the anchor study;Brown DM;Ophthalmology,2009
3. Ranibizumab and bevacizumab for neovascular age-related macular degeneration;Martin DF;N Engl J Med,2011
4. Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week results of the view studies;Schmidt-Erfurth U;Ophthalmology,2014
5. Anti-vascular endothelial growth factor agents in the treatment of retinal disease: From bench to bedside;Campochiaro PA;Ophthalmology,2016